Predictable Winners: How to Improve the Odds of Success in Medtech Innovation

Launching a new medical technology is always a gamble, but according to Ilya Trakhtenberg and Stuart Jackson of L.E.K. Consulting, a systematic, step-by-step approach to innovation can manage risk and unlock the full potential of breakthrough innovation for organizations — far surpassing industry benchmarks.

Most innovations fail. And most companies struggle with innovation. Case in point: Nearly all the growth in the S&P 500 (prior to 2025 YTD) has been driven by just seven companies, the so-called “Magnificent Seven” — Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla. Between 2013 and 2019, they delivered 19% compound returns. The other 493 companies in the index delivered just 2% in that time period. And medtech is no different: the top five market cap growers accounted for 60% of all of the industry’s market cap growth from 2015 to 2024, and a full 80% of it since 2019. Studies show that of the thousands of product launches across industries each year, 70–90% fail.

So how do you bridge that gap if you’re a medtech company looking to succeed with a novel technology? And not only that, but build an enduring franchise?

According to Ilya Trakhtenberg, a partner at L.E.K. Consulting and co-author of the new book, Predictable Winners: A Handbook for Developing, Forecasting, and Launching New Products and Services, in a recent conversation with The Lens, along with his co-author and Vice Chair of L.E.K. Consulting, Stuart Jackson, success is a learnable, doable process.

But this isn’t a book review. It’s a field guide for founders, operators, and commercial leaders who know that FDA clearance alone won’t get your product into the hands of clinicians, or into the standard of care.


This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/predictable-winners-how-to-improve-the-odds-of-success-in-medtech-innovation 

Comments

Post a Comment

Popular posts from this blog

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more

Q1 2025 Medical Device Investment Roundup: A Record-Breaking Start to a Year of Reckoning

Big deals, even bigger questions. Jonathan Norris of HSBC Innovation Banking explains why 2025 is already one for the books. Venture investment across the medical device sector kicked off 2025 with a bang, posting $2.6 billion in first-quarter funding across 132 deals — the highest quarterly dollar mark in three years. According to  Jonathan Norris , Managing Director at  HSBC Innovation Banking , who writes comprehensive reports on the venture healthcare ecosystem, this surge marks a 20% rise in both capital and deal count compared to the 2024 average. “Not only did we have more dollars, but there were more deals, which is really good to see,” Norris says, in a recent interview with  The Lens . “I think the quick and easy takeaway is that more companies were getting funded in Q1, and a good percentage of the bigger deals in the quarter were PMA pivotal trial rounds. It looks like positive momentum for the sector to see a big quarter. That’s our 35,000-foot view.” But ben...
Read more